| Name | Title | Contact Details |
|---|
Priority Dispatch Corporation is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oral Health Products is a Tulsa, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pine Valley Retirement Communi is a Tuscaloosa, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Word & Brown Companies, headquartered in Orange, Calif., provides services through more than 50,000 brokers to nearly 60,000 employers with more than 6 million eligible employees. During its more than 20-year-span, The Word & Brown Companies has become the nation’s recognized leader in developing and offering innovative technology, health benefit plan models, and sophisticated employee benefits services to companies of all sizes. The Word & Brown Companies includes: Word & Brown General Agency, the leader in developing and distributing health benefit plan models and solutions to licensed brokers in California and Nevada; CHOICE Administrators, the nation’s leader in developing and administrating employee-choice health benefit programs; CONEXIS, providing benefits solutions to clients nationwide, with expertise in COBRA and HIPAA administrative services, Direct Bill Services, and Flexible Benefits Administration, including Flexible Spending Accounts (FSA) and Section 132 Commuter Benefits; Quotit Corporation the leading Internet application service provider for the health insurance/employee benefits industry; and HealthCompare, which works with brokers and carriers to help individuals and families easily research, compare, buy, and enroll in the right health insurance plan at the right price.
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China. Our mission is to become an integrated biopharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. Part of our strategy is to leverage our expertise and resources in North America and China to bring safer, more effective, and/or easier-to-use drugs to patients and to develop them more cost-effectively and faster using our unique dual development approach.